Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines

Table 2

Effects of antiresistin RNA oligo on body weight, metabolic parameters, and hepatic enzymes.

Paradigm parameter	Chow	HF-Con-oligo	HF-Res-oligo
After treatment Bwt (g)	28.5 ± 0.9	32.8 ± 1.2^a	32.1 ± 1.7^d
Epididymal fat (g/100 g Bwt)	1.58 ± 0.05	3.3 ± 0.12^b	2.62 ± 0.32^ad
Serum glucose (mM)	6.70 ± 0.75	9.59 ± 0.72^a	7.22 ± 0.30^d
Serum insulin (pg/mL)	528 ± 150	689 ± 121^a	503 ± 164^d
HOMA-IR	22.8 ± 1.9	50.1 ± 6.4^b	27.5 ± 6.2^d
Serum cholesterol (mM)	3.90 ± 0.09	6.87 ± 0.21^b	4.95 ± 0.37^d
Serum triglyceride (mM)	0.63 ± 0.01	0.98 ± 0.02^b	0.79 ± 0.04^d
Serum NEFA (mM)	0.78 ± 0.16	1.03 ± 0.08^a	0.83 ± 0.03^d
Serum ALT (U/L)	29.9 ± 0.6	89.6 ± 9.5^b	52.1 ± 10.3^d
Serum AST (U/L)	32.4 ± 7.9	199.8 ± 21.7^c	65.8 ± 11.7^f
Serum resistin (pg/mL)	513 ± 36	668 ± 35^b	472 ± 19^e

Mice were fed standard chow and high-fat diet for 10 weeks and then with 4-week i.p injection (3 times/week) of saline (Chow, 5 mL/kg of body weight), scrambled control oligo (HF-Con-oligo 25 mg/kg of body weight), or antiresistin RNA oligo (HF-Res-oligo, 25 mg/kg of body weight). Metabolic parameters are represented as mean ± SEM ( each group) after 4 weeks’ treatment. Bwt: body weight; HOMA-IR: homeostatic model assessment-insulin resistance; TG: triglycerides; NEFAs: nonesterified fatty acids; AST: aspartate aminotransferase; ALT: alanine aminotransferase. ^a, ^b, and ^c HF-Con-oligo group versus chow fed mice; ^d, ^e, and ^f versus HF-Con-oligo mice.